Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Study of Aripiprazole in the Treatment of Patients With Psychosis Associated With Dementia of the Alzheimer's Type

This study has been completed.
Sponsor:
Information provided by:
Otsuka Pharmaceutical Development & Commercialization, Inc.
ClinicalTrials.gov Identifier:
NCT00036114
First received: May 7, 2002
Last updated: November 7, 2013
Last verified: April 2011
  Purpose

The purpose of this study is to learn if aripiprazole is safe and effective in the treatment of psychosis associated with dementia of the Alzheimer's type.


Condition Intervention Phase
Alzheimer Disease
Drug: aripiprazole
Phase 3

Study Type: Interventional
Study Design: Primary Purpose: Treatment

Resource links provided by NLM:


Further study details as provided by Otsuka Pharmaceutical Development & Commercialization, Inc.:

Study Start Date: March 2000
Study Completion Date: August 2003
Primary Completion Date: August 2003 (Final data collection date for primary outcome measure)
  Eligibility

Ages Eligible for Study:   55 Years to 95 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Institutionalized patients with Alzheimer's
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00036114

  Hide Study Locations
Locations
United States, Alabama
Local Institution
Tuscaloosa, Alabama, United States
United States, Arizona
Local Institution
Scottsdale, Arizona, United States
United States, California
Local Institution
Cerritos, California, United States
Local Institution
Granada Hills, California, United States
Local Institution
Los Angeles, California, United States
Local Institution
San Diego, California, United States
Local Institution
Torrance, California, United States
United States, Colorado
Local Institution
Denver, Colorado, United States
United States, Connecticut
Local Institution
Hamden, Connecticut, United States
United States, Florida
Local Institution
Miami, Florida, United States
Local Institution
North Miami Beach, Florida, United States
Local Institution
West Palm Beach, Florida, United States
United States, Georgia
Local Institution
Atlanta, Georgia, United States
Local Institution
Augusta, Georgia, United States
Local Institution
Macon, Georgia, United States
United States, Hawaii
Local Institution
Honolulu, Hawaii, United States
United States, Illinois
Local Institution
North Chicago, Illinois, United States
Local Institution
Springfield, Illinois, United States
United States, Louisiana
Local Institution
New Orleans, Louisiana, United States
Local Institution
Shreveport, Louisiana, United States
United States, Maryland
Local Institution
Baltimore, Maryland, United States
United States, Massachusetts
Local Institution
Newton Center, Massachusetts, United States
Local Institution
Springfield, Massachusetts, United States
Local Institution
Wellesley Hills, Massachusetts, United States
United States, New Jersey
Local Institution
Lyons, New Jersey, United States
United States, New York
Local Institution
Albany, New York, United States
Local Institution
Lawrence, New York, United States
Local Institution
Montrose, New York, United States
Local Institution
Northport, New York, United States
Local Institution
White Plains, New York, United States
United States, North Carolina
Local Institution
Raleigh, North Carolina, United States
United States, Ohio
Local Institution
Beachwood, Ohio, United States
United States, Oregon
Local Institution
Portland, Oregon, United States
United States, Pennsylvania
Local Institution
Hershey, Pennsylvania, United States
United States, Texas
Local Institution
Austin, Texas, United States
Local Institution
Dallas, Texas, United States
Local Institution
San Antonio, Texas, United States
Local Institution
Wichita Falls, Texas, United States
United States, Vermont
Local Institution
Bennington, Vermont, United States
United States, Virginia
Local Institution
Charlottesville, Virginia, United States
United States, Washington
Local Institution
Seattle, Washington, United States
Sponsors and Collaborators
Otsuka Pharmaceutical Development & Commercialization, Inc.
  More Information

Additional Information:
No publications provided

ClinicalTrials.gov Identifier: NCT00036114     History of Changes
Other Study ID Numbers: CN138-004
Study First Received: May 7, 2002
Last Updated: November 7, 2013
Health Authority: United States: Food and Drug Administration

Keywords provided by Otsuka Pharmaceutical Development & Commercialization, Inc.:
Psychosis associated with dementia of the Alzheimer's type

Additional relevant MeSH terms:
Alzheimer Disease
Brain Diseases
Central Nervous System Diseases
Delirium, Dementia, Amnestic, Cognitive Disorders
Dementia
Mental Disorders
Nervous System Diseases
Neurodegenerative Diseases
Tauopathies
Aripiprazole
Antipsychotic Agents
Central Nervous System Agents
Central Nervous System Depressants
Pharmacologic Actions
Physiological Effects of Drugs
Psychotropic Drugs
Therapeutic Uses
Tranquilizing Agents

ClinicalTrials.gov processed this record on November 24, 2014